Oral Presentation Australian Diabetes Society and the Australian Diabetes Educators Association Annual Scientific Meeting 2014

The use of Serum Fibrotic Markers to predict NAFLD in obese subjects undergoing bariatric surgery. (#177)

Azni Abdul-Wahab 1 , John Wentworth 1 , Geetha Rathnayake 1 , Paul O’Brien 2 , Cherie Chiang 1
  1. Department of Endocrinology/Biochemistry , Royal Melbourne Hospital, Melbourne
  2. Department of Surgery, Alfred Hospital, Melbourne

Background and Aims: Non-alcoholic fatty liver disease (NAFLD) is prevalent in obese and type 2 diabetes mellitus (T2DM) patients (1-3). NAFLD can progress to cirrhosis and hepatocellular cancer. Predicting disease progression may help select patients for liver biopsy. The Enhanced Liver Fibrosis (ELF) score is calculated from 3 serum markers (tissue inhibitor of metalloproteinases 1, amino-terminal propeptide of type III procollagen and hyaluronic acid), and correlates well with fibrosis in chronic hepatitis population (4,5). Because its performance in the general population of obese people is poorly understood, we determined if ELF score could predict liver fibrosis in obese patients having gastric banding surgery.

Methods: Liver biopsies, clinical and biochemical characteristics of 82 obese people were obtained. Liver fibrosis was determined by histological score and ELF score was determined using fasting serum.

Results: In this cohort (F:M ratio 57:25; age: 46 ± 11 years; BMI: 43 ± 6 kg/m2), 34% had T2DM, 71% had dyslipidaemia and 82% had hypertension. Severe steatosis on biopsy (score 3 and 4) was present in 66% of the entire cohort, and in 71% of T2DM subgroup. Thirty patients (37%) were found to have steatosis and inflammation on biopsy, and three of these had severe fibrosis. Diabetes status and inflammation on biopsy were associated with fibrosis (p< 0.001). An ELF score of <7.7 excluded all cases of moderate/ severe fibrosis, but higher ELF scores were not specific for fibrosis.

Conclusion: In an unselected cohort of obese patients undergoing bariatric surgery, liver steatosis was present in 71% of the diabetic subjects. Diabetes status was associated with fibrosis. A low ELF score excluded all subjects with significant fibrosis. The non-specificity of elevated ELF score in obese subjects might be due to elevated collagen markers such as hyaluronic acid from co-existing osteoarthritis.

  1. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009;13:511–31.
  2. Williamson RM, Price JF, Glancy S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011;34:1139–44
  3. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30:1212–18.
  4. Fernandes FF, Ferraz ML et al. Enhanced Liver Fibrosis Panel as a Predictor of Liver Fibrosis in Chronic Hepatitis C Patients J Clin Gastroenterol. 2014 Apr (Epub).
  5. Gümüşay O, Ozenirler S et al. Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B. Hepatol Res. 2013 Mar;43(3):228-37.